At the same time, the study data allows us to make the assumption that the circulating level of Lp-PLA2 can be evaluated as a possible biomarker of risk and assessment of the response to a certain type of lipid-lowering therapy instituted in patients with chronic ischaemic heart disease. This evidence concerns the gene PLA2G7 and coronary artery disorder.